Synonym
Etilevodopa; L-Dopa ethyl ester; Levodopa ethyl ester; O-Ethyl-DOPA;
IUPAC/Chemical Name
ethyl (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
InChi Key
NULMGOSOSZBEQL-QMMMGPOBSA-N
InChi Code
InChI=1S/C11H15NO4/c1-2-16-11(15)8(12)5-7-3-4-9(13)10(14)6-7/h3-4,6,8,13-14H,2,5,12H2,1H3/t8-/m0/s1
SMILES Code
N[C@@H](CC1=CC=C(O)C(O)=C1)C(OCC)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
225.24
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Gao Q, Ludwig CA, Smith SJ, Schachar IH. Ocular Penetrance and Safety of the Dopaminergic Prodrug Etilevodopa. Transl Vis Sci Technol. 2021 Oct 4;10(12):5. doi: 10.1167/tvst.10.12.5. PMID: 34609478; PMCID: PMC8496415.
2: Djaldetti R, Giladi N, Hassin-Baer S, Shabtai H, Melamed E. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003 Nov- Dec;26(6):322-6. doi: 10.1097/00002826-200311000-00012. PMID: 14646613.
3: Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S, Stern M, Goetz C, Nutt J, Goren S, Sayag N, Scolnik M, Levy R, Eyal E, Salzman P, Pagano M; Parkinson Study Group. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63(2):210-6. doi: 10.1001/archneur.63.2.210. PMID: 16476809.
4: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Apr;25(3):225-48. PMID: 12743628.
5: Singh V, Somvanshi P. Homology modeling of adenosine A2A receptor and molecular docking for exploration of appropriate potent antagonists for treatment of Parkinson's disease. Curr Aging Sci. 2009 Jul;2(2):127-34. doi: 10.2174/1874609810902020127. PMID: 20021407.
6: Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Investig Drugs. 2004 Jul;5(7):720-6. PMID: 15298067.
